Loading...
Loading...
SCPS| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 2.9M |
| Operating I/L | -2,616.6M |
| Other Income/Expense | 2,613.6M |
| Interest Income | 0.0M |
| Pretax | -2.9M |
| Income Tax Expense | 2,613.3M |
| Net Income/Loss | -2.6M |
Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company specializing in developing innovative therapeutics for serious diseases, with a focus on immuno-oncology gene therapy for various cancers. The company's lead development programs include the Duet Platform, featuring CpG signal transducer and STAT3 inhibitors, and MRI-1867, an orally available, dual-action small molecule targeting the endocannabinoid system and inducible nitric oxide synthase. Scopus BioPharma Inc. has established strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem to advance its lead development and other programs.
